



Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis

Jingxuan Lian and Jianfang Fu*

Department of Endocrinology, Xijing Hospital of Air Force Medical University, Xi'an, China

Objective: To systematically evaluate the effects of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD.

Methods: The Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and ClinicalTrials databases were searched until August 2020 for publications written in English. Two reviewers independently assessed study eligibility, continuous data extraction, independent assessment of bias risk, and graded the strength of evidence. Our primary outcomes were the individual number of patients with improvement of at least 1 point in each of the histological parameters. Baseline characteristic data, such as BMI, weight, total body fat, fasting plasma glucose and fasting plasma insulin, and liver biological indicators, such as triglyceride level, HDL cholesterol level, plasma AST, and plasma ALT, were used as secondary outcomes.

OPEN ACCESS

Edited by:

Jehad Ahmed Abubaker, Dasman Diabetes Institute, Kuwait

Reviewed by:

Joseph Aloi, Wake Forest Baptist Medical Center, United States Na Liu, The Second Affiliated Hospital of Xi'an Jiaotong University, China

> *Correspondence: Jianfang Fu Jianff@fmmu.edu.cn

Specialty section:

This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology

Received: 09 October 2020 Accepted: 06 April 2021 Published: 28 April 2021

Citation:

Lian J and Fu J (2021) Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front. Endocrinol. 12:615409. doi: 10.3389/fendo.2021.615409 **Results:** A total of 4 studies were included. Compared with placebo, pioglitazone significantly improved steatosis grade, inflammation grade and ballooning grade, while in the fibrosis stage, there was no significant improvement in pioglitazone compared with placebo. In addition, pioglitazone can also improve blood glucose and liver function.

Conclusion: Pioglitazone can significantly improve the histological performance of the liver and insulin sensitivity. Additionally, it can significantly reduce fasting blood glucose, glycosylated hemoglobin, plasma AST, ALT and other liver biological indicators. Due to the lack of relevant randomized controlled trials and short intervention times, long-term studies are still needed to verify its efficacy and safety.

Systematic Review Registration: [PROSPERO], identifier [CRD42020212025].

Keywords: NAFLD, type 2 diabetes mellitus, pioglitazone, meta-analysis, prediabetes

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is a liver disease caused by damage to the liver unrelated to alcohol; NAFLD can develop into nonalcoholic steatosis (NASH), advanced fibrosis and hepatocellular carcinoma (HCC) (1). NAFLD is the fastest growing cause of HCC among liver transplantation candidates (2). NAFLD may also be involved in the pathogenesis of type 2 diabetes and atherosclerosis. Researchers recently reported that the global prevalence of NAFLD in T2DM patients was 55.5% (3).

The European Association for the Study of Obesity recommends in the NAFLD Clinical Practice Guidelines that screening for NAFLD in T2DM patients, although weight reduction is the basis for the treatment of NAFLD, drug therapy is also necessary because weight reduction alone is difficult to maintain therapeutic effects (4). In patients with T2DM complicated with NAFLD, the use of antidiabetic drugs is more effective than lifestyle changes in controlling glucose levels (5). In addition, lifestyle changes, combined with antidiabetic drugs, may reduce cardiovascular disease-related risk factors and liver fat accumulation and delay the progression of NASH and fibrosis. While there is no recognized drug for the treatment of NAFLD, many antidiabetic drugs have been tested in NAFLD patients due to the common epidemiological and pathophysiological characteristics between NAFLD and T2DM (6).

Pioglitazone, a thiazolidinedione derivative, is a peroxisome proliferator–activated receptor γ (PPAR γ) agonist that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes (7, 8). Although a number of randomized controlled trials have been conducted to study the efficacy of pioglitazone in NAFLD combined with T2DM or prediabetes, there is no systematic review on randomized controlled trials (RCTs) of pioglitazone. Therefore, through the latest randomized controlled trials, we systematically reviewed the advantages and disadvantages of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD.

METHODS

Data Sources and Search Strategy

The systematic review scheme used in this study is reported in accordance with the preferred reporting items listed in the guidelines for systematic review and meta-analysis (PRISMA-P) (9). Our PROSPERO registration ID is CRD42020212025.

We performed electronic searches in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and ClinicalTrials. We searched each database until August 2020, and the language was limited to English (the complete search strategy is shown in Appendix 1). The preferred reporting items of the systematic review and metaanalysis guidelines were followed at all stages of the study (the complete protocol is shown in Appendix 2).

Inclusion and Exclusion Criteria

We included a double-blind, placebo-controlled RCT of the effects of pioglitazone on patients aged between 18 and 70 with prediabetes or T2DM combined with NAFLD. Intervention duration < 4 weeks or any cause of chronic liver disease other than NAFLD and suffering from other types of chronic diseases, such as hypertension and coronary heart disease, were excluded, and studies that did not differentiate patients in the subgroup analysis were excluded. In addition, long-term use of hypoglycemic drugs, prescription drugs for the treatment of other chronic diseases, food supplements, and other nonhyperglycemic drugs (such as liver protection drugs) were excluded. For the crossover RCTs, the carrying effect is considered; therefore, we used the data from the first phase of the study.

Study Selection and Data Extraction

Two reviewers independently screened and identified the study and resolved their differences through discussion. In addition, a manual search of references in published systematic reviews and meta-analyses was performed to ensure that no studies were missing. Data were independently extracted to an Excel spreadsheet according to previously defined criteria. For each of the included studies, we extracted data such as study time, trial design, intervention measures and time, demographics, and baseline characteristics.

Our primary outcomes were the individual number of patients with improvement of at least 1 point in each of the histological parameters, which included four aspects: steatosis grade, inflammation grade, ballooning grade and fibrosis stage. Second, it includes resolution of NASH without worsening of fibrosis and individual histological score number of patients with improvement of at least 2 points from two different parameters. Our secondary outcomes were baseline characteristic data, such as BMI, weight, total body fat, fasting plasma glucose and fasting plasma insulin, and liver biological indicators, such as triglyceride level, HDL cholesterol level, plasma AST, and plasma ALT.

Quality Assessment

The Cochrane collaborative risk assessment tool was used to assess the risk of bias for each included study. The following aspects were evaluated: random sequence generation, allocation hiding, blindness of participants and personnel, blindness of result evaluation, incomplete result data, selective reporting and other biases. GRADE Pro (V.3.6) software was used to rate the overall quality of evidence for each outcome based on five evaluation criteria: risk of bias, inconsistency, indirectness, imprecision, and publication bias.

Data Synthesis and Statistical Analysis

For continuity variables, we used the standardized mean difference (SMD) and 95% CI for analysis. The meanings of SMD values should be interpreted as follows: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. For dichotomous variables, we calculated the risk ratio of the 95% CI. We used changes before and after the intervention to assess the effectiveness of different drugs and placebos. When SD was not reported in the study, we derived SD from other studies included in the meta-analysis. We used P=0.05 as the statistically significant threshold. Meta-analysis software (RevMan V.5.3) was used for analysis, and heterogeneity was evaluated according to I2: 25%, 50 and 75% values were judged as mild, moderate and substantial heterogeneity, respectively. The random effects model was used to reduce the effect of heterogeneity. GRADE Pro (V.3.6) software was used to rate the overall quality of evidence for each outcome based on five evaluation criteria: risk of bias, inconsistency, indirectness, imprecision, and publication bias.

RESULTS

We found a total of 137 articles from the target database, among which 138 full-text papers were qualified, and 20 full-text papers were excluded according to the research exclusion criteria (**Figure 1**). A total of 4 RCTs of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD met the inclusion criteria (9–12). Most of the trials were conducted in the United States, including one in China, where the intervention duration was more than four months, with a maximum of 18 months.

Through the risk assessment using the Cochrane Collaboration risk assessment tool, it was found that the overall risk was moderate to low (**Figure 2**), which was mainly caused by allocation concealment, selective reporting, incomplete data, and unclear blind reporting in some studies.

Primary Outcomes

The meta-analysis showed (**Figure 3**) that in terms of the liver histological score, compared with placebo, pioglitazone significantly improved the steatosis grade [RR 1.78 (95% CI 1.05, 3.04, p = 0.03, $I^2 = 76\%$)], and the quality of the evidence was very low [summary of findings (SoF) **Table 1**]. There were also significant differences in inflammation grade [RR2.05 (95% CI

1.50, 2.80, p<0.00001, $I^2 = 0\%$; SoF **Table 1**)] and ballooning grade [RR 1.74 (95% CI 1.26, 2.40, p= 0.0007, $I^2 = 48\%$; SoF **Table 1**)]. However, in the fibrosis stage (**Figure 3D**), there was no significant improvement in pioglitazone compared with placebo [RR 1.25 (95% CI 0.90, 1.71, p= 0.18, $I^2 = 48\%$; SoF **Table 1**)]. In terms of the resolution of NASH (**Figure 3E**), compared with placebo, pioglitazone also significantly improved the rate of NASH resolution [RR1.76 (95% CI 1.18, 2.62, p= 0.005, $I^2 = 30\%$; SoF **Table 1**)]. In terms of individual histological scores, the number of patients with improvement of at least 2 points from two different parameters (**Figure 3F**) was also significantly higher in the pioglitazone group than in the placebo group [RR2.35 (95% CI 1.29, 4.29, P = 0.005, $I^2 = 55\%$; SoF **Table 1**)].

Basic Characteristics

In terms of weight, although pioglitazone was found to increase the weight of patients in some studies, the meta-analysis showed that pioglitazone did not significantly increase the weight (**Figure 4A**) of patients compared with placebo (SMD0.04 [95% CI -0.20, 0.28, p=0.75, $I^2 = 0\%$)] or BMI [SMD0.19 (95% CI -0.02, 0.40, p=0.08, $I^2 = 39\%$; **Figure 4B**)]. For total body fat, the meta-analysis showed no significant difference between placebo and pioglitazone [SMD0.15 (95% CI -0.12, 0.41, p=0.28, $I^2 = 2\%$; **Figure 4C**)]. In





FIGURE 2 | Risk of bias summary for review authors judgments about each risk of bias item for each included stud

regard to glucose metabolism, only in HOMA-IR, pioglitazone was not significantly different from placebo [SMD -0.44 (95%CI -1.04, 0.15,p= 0.14, $I^2 = 79\%$; **Figure 4D**)], In addition, in fasting plasma glucose (SMD -0.68 [95%CI -0.95, -0.41, p<0.00001, $I^2 = 0\%$; **Figure 4E**)], fasting plasma insulin [SMD -0.55 (95%CI -0.82, -0.28, p<0.00001, $I^2 = 0\%$; **Figure 4F**)] and HbA1c [SMD -0.77 (95%CI -0.99 -0.55, p<0.00001, $I^2 = 0\%$; **Figure 4G**)], pioglitazone was significantly lower than the placebo group, indicating that pioglitazone can significantly improve the glucose metabolic function of patients.

Biological Indicators of Liver

We also analyzed other biomarkers of the liver, and metaanalysis showed that compared with placebo, pioglitazone could significantly reduce the plasma AST (SMD-0.21 [95% CI -0.42, 0.00, p= 0.05, $I^2 = 34\%$; **Figure 5A**)] and ALT [SMD -0.36 (95% CI-0.57, -0.14, p= 0.03, $I^2 = 66\%$; **Figure 5B**)] levels in patients and significantly improve the liver function of patients. Pioglitazone also significantly increased patients' HDL levels [SMD 0.28 (95%CI 0.07, 0.50, p= 0.009, $I^2 = 0\%$; **Figure 5C**)], but there was no significant change in LDL levels compared with placebo [SMD 0.16 (95%CI -0.18, 0.51, p= 0.35, $I^2 = 59\%$; **Figure 5D**)]. Moreover, there was no significant difference in triglyceride levels between the pioglitazone group and the placebo group [SMD -0.20 (95% CI -0.51, 0.12, p= 0.22, I2 = 52%; **Figure 5E**)].

Adverse Events

Meta-analysis showed that pioglitazone was significantly more likely to cause adverse events than placebo [RR 1.65 (95% CI 1.13, 2.42, p= 0.01, I2 = 45%; **Figure 6A**)]. The risk of experiencing individual adverse events of hypoglycemia, chronic lower limb edema, atypical chest pain or epigastralgia and back or joint pain was significantly increased with pioglitazone compared with placebo. However, there was no significant increase in the risk of pioglitazone discontinuation due to adverse events compared to placebo [RR 1.30 (95% CI 0.81, 2.09, p= 0.27, I2 = 0%; **Figure 6B**)].

There was also no significant difference in the risk of serious adverse events between pioglitazone and placebo [RR 1.53 (95% CI 0.77, 3.05, p= 0.23, $I^2 = 0\%$; **Figure 6C**)]. In total, four deaths were reported across 1 trial, two in the pioglitazone group and two in the placebo group.

	Church a see Carls an area		Placebo			Risk Ratio	Risk Ratio M-H, Random, 95% Cl				
	Study or Subgroup Belfort 2006	Events T 17	26			<u>еідпт м-н</u> 8.0%	I. Random, 95% CI 1.72 [0.93, 3.17]		M-H, Randoi	m, 95% CI	_
	Bril 2019	32	37			0.1%	1.30 [1.00, 1.69]		-		
	Cusi 2016	35	50			1.9%	2.75 [1.66, 4.54]				
	Total (95% CI)		113	11	08 10	0.0%	4 79 14 05 2 041				
	Total events	84	115	45	00 10	0.0%	1.78 [1.05, 3.04]				
	Heterogeneity: Tau ² =		8.43, df:		.01); l²	= 76%	-	+		<u> </u>	<u> </u>
	Test for overall effect:						l	0.2	0.5 1	2	5
								а	In RR of 1.78 favors p	-	acebo
3	Study or Subgroup	Pioglita		Placeh		Mainht	Risk Ratio			Ratio ed, 95% Cl	
	Belfort 2006	Events 22	26	Events 8	21	26.1%	M-H, Fixed, 95% Cl		M-H, FIXe	ed, 95% CI	
	Bril 2019	22	37	13	36	38.9%	2.22 [1.26, 3.92] 1.87 [1.15, 3.05]				_
	Cusi 2016	25	50	12	51	35.0%	2.13 [1.21, 3.75]				
	00312010	20	50	12	51	33.070	2.10 [1.21, 0.70]				
	Total (95% CI)		113		108	100.0%	2.05 [1.50, 2.80]			-	
	Total events	72		33							
	Heterogeneity: Chi ²				9%			0.2	0.5	1 2	5
	Test for overall effec	ct: Z = 4.51 (P < 0.00	001)					In RR of 2.05 favors p	nioglitazone, not pl	acebo
				-							
>	Church and Carbonness	Pioglita		Placel		18/ - inter	Risk Ratio			Ratio	
	Study or Subgroup Belfort 2006	Events 14	26	Events 5	21	16.0%	M-H, Fixed, 95% Cl 2.26 [0.97, 5.26]		MI-H, FIX	ed, 95% Cl	
	Bril 2019	23	37	18	36		1.24 [0.82, 1.88]				
	Cusi 2016	25	50	11	51	31.4%	2.32 [1.28, 4.19]			-	
	00012010	20	00		0.	01.470	2.02 [1.20, 4.10]				
	Total (95% CI)		113		108	100.0%	1.74 [1.26, 2.40]				
	Total events	62		34							
	Heterogeneity: Chi ²	^e = 3.84, df=	2(P = 0	.15); I ² =	48%			0.2	0.5	1 2	5
									n RR of 1.74 favors p	In all farmers and all	
								a			acebo
5	Study or Subgroup	Pioglita		Place		Weight	Risk Ratio	a	Risk	Ratio	acebo
)	Study or Subgroup Belfort 2006	Events	Total	Events	Total		M-H, Fixed, 95% Cl	a	Risk		acebo
0	Belfort 2006	Events 12	Total 26	Events 7	Total 21	19.4%	M-H, Fixed, 95% Cl 1.38 [0.66, 2.88]	a	Risk	Ratio	acebo
D		Events	Total	Events	Total	19.4% 48.3%	M-H, Fixed, 95% Cl	a	Risk	Ratio	acebo
D	Belfort 2006 Bril 2019 Cusi 2016	<u>Events</u> 12 19	Total 26 37 50	Events 7 19	Total 21 36 51	19.4% 48.3% 32.3%	<u>M-H, Fixed, 95% CI</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80]	a.	Risk	Ratio	acebo
D	Belfort 2006 Bril 2019 Cusi 2016 Total (95% Cl)	5 Events 12 19 20	Total 26 37	Events 7 19 13	Total 21 36 51	19.4% 48.3%	M-H, Fixed, 95% Cl 1.38 [0.66, 2.88] 0.97 [0.63, 1.51]	a.	Risk	Ratio	acebo
D	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events	 Events 12 19 20 51 	Total 26 37 50 113	Events 7 19 13 39	Total 21 36 51 108	19.4% 48.3% 32.3%	<u>M-H, Fixed, 95% CI</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80]		Risk <u>M-H, Fix</u> 	Katio ed, 95% Cl	
D	Belfort 2006 Bril 2019 Cusi 2016 Total (95% Cl)	Events 12 19 20 51 ² = 1.90, df =	<u>Total</u> 26 37 50 113 = 2 (P = 0	Events 7 19 13 39 0.39); ² =	Total 21 36 51 108	19.4% 48.3% 32.3%	<u>M-H, Fixed, 95% CI</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
D	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*]	Events 12 19 20 51 ² = 1.90, df =	<u>Total</u> 26 37 50 113 = 2 (P = 0	Events 7 19 13 39 0.39); ² =	Total 21 36 51 108	19.4% 48.3% 32.3%	<u>M-H, Fixed, 95% CI</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi Test for overall effe	2 Events 12 19 20 51 ² = 1.90, df = ect: Z = 1.35 Pioglita	<u>Total</u> 26 37 50 113 : 2 (P = ((P = 0.1) zone	Events 7 19 13 39 0.39); I ² = 3) Placeb	<u>Total</u> 21 36 51 108 0%	19.4% 48.3% 32.3%	M.H, Fixed, 95% CI 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
5	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*] Test for overall effe Study or Subgroup	Events 12 19 20 *= 1.90, df= :ct: Z = 1.35 Pioglita :events	Total 26 37 50 113 : 2 (P = 0 (P = 0.18 zone Total	Events 7 19 13 39 0.39); I ² = 8) Placeb Events	Total 21 36 51 108 0% 0%	19.4% 48.3% 32.3% 100.0%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u>		Risk <u>M-H, Fix</u> 	Ratio ed. 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*] Test for overall effe <u>Study or Subgroup</u> Belfort 2006	Events 12 19 20 51 *= 1.90, df= :ct: Z = 1.35 Pioglita Events 17	Total 26 37 50 113 : 2 (P = 0 (P = 0.18 zone Total 26	Events 7 19 13 39 .39); I² = 39 .29); I² = 8) Placeb Events 8	Total 21 36 51 108 0% 0% 0 <u>fotal</u> 21	19.4% 48.3% 32.3% 100.0% <u>Weight M</u> 28.0%	<u>M.H. Fixed, 95% CI</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A.H. Random, 95% CI</u> 1.72 [0.93, 3.17]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*] Test for overall effe Study or Subgroup	Events 12 19 20 *= 1.90, df= :ct: Z = 1.35 Pioglita :events	Total 26 37 50 113 : 2 (P = 0 (P = 0.18 zone Total	Events 7 19 13 39 0.39); I ² = 8) Placeb Events	Total 21 36 51 108 0% 0%	19.4% 48.3% 32.3% 100.0% <u>Weight M</u> 28.0% 40.1%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*] Test for overall effe <u>Study or Subgroup</u> Belfort 2006 Bril 2019 Cusi 2016	Events 12 19 20 51 *= 1.90, df= ict: Z = 1.35 Pioglita Pioglita 17 32	Total 26 37 50 113 2 (P = 0 (P = 0.18 20ne Total 26 37 50	Events 7 19 13 39	Total 21 36 51 108 0% 0% 0% 0% 21 36 51	19.4% 48.3% 32.3% 100.0% <u>Weight N</u> 28.0% 40.1% 31.9%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi Test for overall effe <u>Study or Subgroup</u> Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI)	Events 12 19 20 51 = 1.90, df= ict: Z = 1.35 Pioglita 17 32 35	Total 26 37 50 113 : 2 (P = 0 (P = 0.1) zone Total 26 37	Events 7 19 13 39 39; i² = 39 39; i² = 8) Placeb Events 8 24 13	Total 21 36 51 108 0% 0% 0% 0% 21 36 51	19.4% 48.3% 32.3% 100.0% <u>Weight M</u> 28.0% 40.1%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ^a Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events	Events 12 19 20 51 *= 1.90, df= :ect: Z = 1.35 Pioglita 17 32 35 84	Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20 20 20 37 50 113	Events 7 19 13 39	Total 21 36 51 108 0% 0 <u>fotal</u> 21 36 51 108	19.4% 48.3% 32.3% 100.0% <u>Weight N</u> 28.0% 40.1% 31.9% 100.0%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Risl <u>M-H, Ran</u>	K Ratio ed, 95% Cl	1 iacebo
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ¹ Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau	Events 12 19 20 51 ² = 1.90, df = ict: Z = 1.35 Pioglita 17 32 35 84 ² = 0.17; Chi	Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20 Total 26 37 50 113 ² = 8.43,	Events 7 19 13 39	Total 21 36 51 108 0% 0 <u>fotal</u> 21 36 51 108	19.4% 48.3% 32.3% 100.0% <u>Weight N</u> 28.0% 40.1% 31.9% 100.0%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54]		Risk <u>M-H, Fix</u> 	K Ratio ed, 95% Cl	
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ^a Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events	Events 12 19 20 51 ² = 1.90, df = ict: Z = 1.35 Pioglita 17 32 35 84 ² = 0.17; Chi	Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20 Total 26 37 50 113 ² = 8.43,	Events 7 19 13 39	Total 21 36 51 108 0% 0 <u>fotal</u> 21 36 51 108	19.4% 48.3% 32.3% 100.0% <u>Weight N</u> 28.0% 40.1% 31.9% 100.0%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Risl <u>M-H, Ran</u>	K Ratio ed, 95% Cl	1 5 acebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ¹ Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau	Events 12 19 20 51 *= 1.90, df= ict: Z = 1.35 Pioglita 0 Events 17 32 35 84 *= 0.17; Chi ct: Z = 2.12 (Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20ne Total 26 37 50 113 ² = 8.43, P = 0.03;	Events 7 19 13 39 39 0.39); I² = 39 Placeb 5 Events 8 24 13 45 45 df = 2 (P =	Total 21 36 51 108 0% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	19.4% 48.3% 32.3% 100.0% <u>Weight N</u> 28.0% 40.1% 31.9% 100.0%	<u>M-H, Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A-H, Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ran</u> 0.5	k Ratio ed. 95% Cl	1 5 acebo
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ¹ Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau	Events 12 19 20 51 = 1.90, df= ict: Z = 1.35 Pioglita 17 32 35 #= 0.17; Chi ct: Z = 2.12 (Total 26 37 50 113 = 2 (P = 0 (P = 0.18 26 37 50 113 = 8.43, P = 0.03; tazone	Events 7 19 13 39 .39); I² = 9 .39); I² = 8 24 13 .45 df = 2 (P = Placeb	Total 21 36 51 108 0 % 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	19.4% 48.3% 32.3% 100.0% 100.0% 28.0% 40.1% 31.9% 100.0% ; I ² = 76%	<u>M.H. Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M.H. Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ram</u> 0.5 In RR of 1.78 favors p Riss	K Ratio ed, 95% Cl	1 5 acebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ^T Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau Test for overall effe	Events 12 19 20 51 = 1.90, df= ict: Z = 1.35 Pioglita 17 32 35 #= 0.17; Chi ct: Z = 2.12 (Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20 26 37 50 113 = 8.43, P = 0.03) tazone = Total	Events 7 19 13 39 .39); I² = 9 .39; I² = 9	Total 21 36 51 108 0 % 0 % 0 % 0 % 0 % 0 % 108 51 108 € 0.01) 21 36 51 108 € 0.01)	19.4% 48.3% 32.3% 100.0% 100.0% 28.0% 40.1% 31.9% 100.0% ; I ² = 76%	<u>M-H, Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A-H, Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04] Risk Ratio <u>t M-H, Fixed, 95% C1</u>		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ram</u> 0.5 In RR of 1.78 favors p Riss	K Ratio ed, 95% Cl	1 5 acebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*] Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau Test for overall effe	Events 12 19 20 51 = 1.90, df = ict: Z = 1.35 Pioglita 17 32 35 84 = 0.17; Chi ct: Z = 2.12 (Pioglita pioglita	Total 26 37 50 113 2 (P = 0 (P = 0.18 20 20 10 26 37 50 113 27 50 113 28 28 37 50 113 28 37 50 113 28 20 113 28 20 113 28 20 113 28 20 113 28 20 113 28 20 113 28 20 10 10 10 10 10 10 10 10 10 1	Events 7 19 13 39 .39); I² = 9 .39, I² = 9	Total 21 36 51 108 0% 0	19.4% 48.3% 32.3% 100.0% 100.0% 40.1% 31.9% 100.0% ; [* = 76% al Weight 6 57.0%	<u>M-H, Fixed, 95% C1</u> 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>M-H, Random, 95% C1</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04] Risk Ratio <u>t M-H, Fixed, 95% C1</u> 5 1.39 [0.84, 2.31]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ram</u> 0.5 In RR of 1.78 favors p Riss	K Ratio ed, 95% Cl	1 5 acebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ¹ Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau Test for overall effe Study or Subgroup Bril 2019 Cusi 2016	Events 12 19 20 51 2 2 1.90, df= 100, df= 100, df= 11, 200, df=	Total 26 37 50 113 = 2 (P = 0 (P = 0.18) zone Total 26 37 50 113 26 37 50 113 *= 8.43, P = 0.03; tazone <u>azone</u> <u>Total</u> 37 50	Events 7 19 13 39 13 .39); I² = 39 Placeb 8 24 13 45 24 13 45 df = 2 (P = 9 Placet 14 3 10	Total 21 36 51 108 0% 0	19.4% 48.3% 32.3% 100.0% 40.1% 31.9% 100.0% (1 ² = 76% a) Weight 6 57.0% 1 43.0%	M-H, Fixed, 95% CI 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A.H, Random, 95% CI</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04] Risk Ratio <u>H.H, Fixed, 95% CI</u> 5 1.39 [0.84, 2.31] 5 2.25 [1.20, 4.20]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ram</u> 0.5 In RR of 1.78 favors p Riss	K Ratio ed, 95% Cl	1 5 acebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ^T Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau Test for overall effe Study or Subgroup Bril 2019 Cusi 2016 Total (95% CI)	Events 12 19 20 51 *= 1.90, df= ict: Z = 1.35 Pioglita 17 32 35 *= 0.17; Chi ct: Z = 2.12 (Pioglita 17 32 35 20 21 22 22 24 25	Total 26 37 50 113 = 2 (P = 0 (P = 0.18) Zone Total 26 37 50 113 = 2 (P = 0.18) Zone Total 26 37 50 113 = 8.43, P = 0.03; tazone 5 50	Events 7 19 13 39 .39); r = 9 .39); r = 8 .24 13 .45 df = 2 (P = Place Place.1 Events 1 9 10 10	Total 21 36 51 108 0% 0 7 0 7 0 7 0 7 0 7 0 7 108 51 108 51 108 51 108 51 51 108 51 51 108 51 51 108 51 51 108 0% 8 8 8 8 8 8 8 8 8 8 8 8 9 8 9 8 9	19.4% 48.3% 32.3% 100.0% 100.0% 40.1% 31.9% 100.0% ; [* = 76% al Weight 6 57.0%	M-H, Fixed, 95% CI 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A.H, Random, 95% CI</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04] Risk Ratio <u>H.H, Fixed, 95% CI</u> 5 1.39 [0.84, 2.31] 5 2.25 [1.20, 4.20]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ram</u> 0.5 In RR of 1.78 favors p Rist	K Ratio ed, 95% Cl	1 5 acebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi [*] Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau Test for overall effe Study or Subgrou Bril 2019 Cusi 2016 Total (95% CI) Total events	Events 12 19 20 51 = 1.90, df = ict: Z = 1.35 Pioglita 17 32 35 84 = 0.17; Chi ct: Z = 2.12 (Pioglita 20 21 22 24	Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20 26 37 50 113 = 8.43, P = 0.03 tazone <u>5</u> 5 5 5 5 5 5 5 5 5 5 5 5 5	Events 7 19 13 39 .39); ² = 9 .39); ² = 9 .39); ² = 9 .39); ² = 9 .39); ² = 9 .39); ² = 9 .39); ² = 9 .45 0 .45 0 .12 9 .12<	Total 21 36 51 108 0% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	19.4% 48.3% 32.3% 100.0% 100.0% 28.0% 40.1% 31.9% 100.0% ; I ² = 76% 1 Weight 6 57.0% 1 43.0% 7 100.0%	M-H, Fixed, 95% CI 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A.H, Random, 95% CI</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04] Risk Ratio <u>H.H, Fixed, 95% CI</u> 5 1.39 [0.84, 2.31] 5 2.25 [1.20, 4.20]		Risk M-H, Fix 0.5 In RR of 1.25 favors p Rist M-H, Ram 0.5 In RR of 1.78 favors p Ris M-H, Fi	k Ratio dorn, 95% Cl	lacebo
Ξ	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Chi ^T Test for overall effe Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Total events Heterogeneity: Tau Test for overall effe Study or Subgroup Bril 2019 Cusi 2016 Total (95% CI)	Events 12 19 20 51 $= 1.90, df =$ ict: Z = 1.35 Pioglita 17 32 35 events 17 32 35 Pioglita 17 32 35 84 $= 0.17; Chi ct: Z = 2.12 (Pioglita 20 21 22 42 ii2 = 1.42, df $	Total 26 37 50 113 = 2 (P = 0 (P = 0.18 20 26 37 50 113 = 8.43, P = 0.03; tazone <u>5</u> 5 5 5 5 5 5 5 5 5 5 5 5 5	Events 7 19 13 39 .39); ² = 9 .39); ² = 9 .39); ² = 9 .39); ² = 9 .39); ² = 9 .24 13 .45 df = 2 (P = 9 9 9 9 9 9 9 9 10 10 10 10 10 10 10 10 10 11 12 13	Total 21 36 51 108 0% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	19.4% 48.3% 32.3% 100.0% 100.0% 28.0% 40.1% 31.9% 100.0% ; I ² = 76% 1 Weight 6 57.0% 1 43.0% 7 100.0%	M-H, Fixed, 95% CI 1.38 [0.66, 2.88] 0.97 [0.63, 1.51] 1.57 [0.88, 2.80] 1.25 [0.90, 1.71] Risk Ratio <u>A.H, Random, 95% CI</u> 1.72 [0.93, 3.17] 1.30 [1.00, 1.69] 2.75 [1.66, 4.54] 1.78 [1.05, 3.04] Risk Ratio <u>H.H, Fixed, 95% CI</u> 5 1.39 [0.84, 2.31] 5 2.25 [1.20, 4.20]		Risk <u>M-H, Fix</u> 0.5 In RR of 1.25 favors p Rist <u>M-H, Ram</u> 0.5 In RR of 1.78 favors p Rist	K Ratio ed, 95% Cl	1 5 acebo

FIGURE 3 | The effect of pioglitazone in hepatic histologic scores(steatosis grade) with improvement of at least 1 grade (A); The effect of pioglitazone in hepatic histologic scores(Inflammation grade) with improvement of at least 1 grade (B); The effect of pioglitazone in hepatic histologic scores(ballooning grade) with improvement of at least 1 grade (C); The effect of pioglitazone in hepatic histologic scores(fibrosis stage) with improvement of at least 1 grade (D); The effect of pioglitazone in reduction of at least 2 points in hepatic histologic scores (from two different parameters) (F).

TABLE 1 | Pioglitazone compared to Placebo for NAFLD Patients with Prediabetes or Type 2 Diabetes Mellitus.

Patient or population: NAFLD Patie Outcomes		s or Type 2 Diabetes Melli parative risks* (95% CI)	us Settings: Interve Relative effect (95% Cl)	ntion, Pioglitazone No of Participants	, Comparison, Place Quality of the evidence	ebo Comments
	Assumed risk Placebo	Corresponding risk Pioglitazone	(95% CI)	(studies)	(GRADE)	
Hepatic Histologic Scores with	Study	population	RR 1.78	221	$\oplus \Theta \Theta \Theta$	
improvement of at least 1 grade (Steatosis grade)	417 per 1000	742 per 1000 (437 to 1000)	(1.05 to 3.04)	(3 studies)	very low ^{1,2,3}	
	м	oderate				
	381 per 1000	678 per 1000 (400 to 1000)				
Hepatic Histologic Scores with	Study	population	RR 2.05	221	$\oplus \oplus \oplus \ominus$	
improvement of at least 1 grade (Inflammation grade)	306 per 1000	626 per 1000 (458 to 856)	(1.5 to 2.8)	(3 studies)	moderate ^{2,3,4}	
(м	oderate				
	361 per 1000	740 per 1000 (541 to 1000)				
Hepatic Histologic Scores with	Study	population	RR 1.74	221	$\oplus \Theta \Theta \Theta$	
(Ballooning grade)	315 per 1000	548 per 1000 (397 to 756)	(1.26 to 2.4)	(3 studies)	very low ^{1,2,3}	
(Dancorning grado)	м	oderate				
	238 per 1000	414 per 1000				
	200 poi 1000	(300 to 571)				
Hepatic Histologic Scores with	Study	population	RR 1.25	221	$\oplus \oplus \Theta \Theta$	
(Fibrosis stage)	361 per 1000	451 per 1000 (325 to 618)	(0.9 to 1.71)	(3 studies)	low ^{2,3}	
(м	oderate				
	333 per 1000	416 per 1000 (300 to 569)				
Resolution of NASH without	Study	population	RR 1.76	183	$\oplus \Theta \Theta \Theta$	
worsening of fibrosis	276 per 1000	486 per 1000 (326 to 723)	(1.18 to 2.62)	(2 studies)	very low ^{2,3,5}	
	м	oderate				
	293 per 1000	516 per 1000 (346 to 768)				
reduction of at least 2 points in	Study	population	RR 2.35	174	$\oplus \oplus \Theta \Theta$	
Hepatic Histologic Scores	253 per 1000	594 per 1000	(1.29 to 4.29)	(2 studies)	low ^{1,2,3,4}	
Hepatic (from two different parameters)	M	(326 to 1000) oderate	. ,	. ,		
,	269 per 1000	632 per 1000 (347 to 1000)				

GRADE Working Group grades of evidence.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹Substantial heterogeneity.

²Some of the studies had adjuvant therapeutic measures, which to some extent led to indirect comparisons.

³Subjects which the study include was insufficient.

, 4RR > 2.

⁵Moderate heterogeneity.

Publication Bias

Since we included fewer than 10 articles, publication bias testing was not recommended according to the Cochrane Collaboration Handbook. However, to better evaluate our research results, we performed a publication bias analysis on the primary outcomes by funnel plots. The visual inspection of funnel plots of our primary outcomes did not suggest potential publication bias (**Figure 7**).

For our primary outcomes, sensitivity analysis was used to assess the impact of each individual study on the pooled results by sequentially remove each eligible study. Deletion of any study has no significant effect on the results, indicating that the results were statistically stable and reliable.

DISCUSSION

Nonalcoholic fatty liver disease is a frequently neglected and undertreated condition among patients with T2DM. Recent studies indicate that most obese patients with T2DM have

		Piogl	itazon	е	Pla	acebo			Std. Mean Difference	Std. Mean Difference
-	Study or Subgroup	Mean			Mean			Weight		IV, Fixed, 95% Cl
	Belfort 2006	96.2		26	89.7		21			
	Cusi 2016 Yan 2015	99.4 73	16.6 16.8	51 60	99.5 73.7		50 62	37.6% 45.4%		
	Total (95% CI)			137			133	100.0%		•
	Heterogeneity: Chi ² =	1 46 df=	2 (P :		· 12 = 0.9		155	100.070		
	Test for overall effect:				0 .	, ,				-1 -0.5 0 0.5 1 Favours (pioglitazonel) Favours (control)
в	Study or Subgroup	Piogl Mean	litazon SD			sD	Total	Weight	Std. Mean Difference IV, Fixed, 95% CI	Std. Mean Difference IV, Fixed, 95% Cl
	Belfort 2006	34.6	5.7	26	32.7		21	13.5%	0.36 [-0.22, 0.94]	
	Bril 2019	36.6	2.9	37	33.9		36	20.6%	0.61 [0.14, 1.08]	
	Cusi 2016	34.6	4.8	50	34.6	5	51	29.9%	0.00 [-0.39, 0.39]	_
	Yan 2015	26.8	4.8	60	26.6		62		0.05 [-0.31, 0.40]	
	Total (95% CI)			173			170	100.0%	0.19 [-0.02, 0.40]	•
	Heterogeneity: Chi ² =				; I ² = 39	9%			-	-1 -0.5 0 0.5 1
	Test for overall effect:	:Z=1.76	(P = 0	.08)						Favours [pioglitazonel] Favours [control]
с		-	litazon			icebo			Std. Mean Difference	Std. Mean Difference
-	Study or Subgroup	Mean						Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
	Belfort 2006	35.2	6.1	26	34.9		21	21.2%	0.04 [-0.54, 0.61]	
	Bril 2019	40	7	37	37	7	36	32.6%	0.42 [-0.04, 0.89]	
	Cusi 2016	36	8	50	36	7	51	46.2%	0.00 [-0.39, 0.39]	
	Total (95% CI)			113			108	100.0%	0.15 [-0.12, 0.41]	•
	Heterogeneity: Chi ² =				; I ² = 2%	6			_	-1 -0.5 0 0.5 1
	Test for overall effect:	:Z=1.08	(P = 0	.28)						Favours [pioglitazonel] Favours [control]
D		Diod	litazon	•	DIa	icebo			Std. Mean Difference	Std. Mean Difference
	Study or Subgroup	Mean			Mean		Fotal	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
	Belfort 2006	35.2	6.1	26	34.9	8.8	21	21.2%	0.04 [-0.54, 0.61]	
	Bril 2019	40	7	37	37	7	36	32.6%	0.42 [-0.04, 0.89]	
	Cusi 2016	36	8	50	36	7	51	46.2%	0.00 [-0.39, 0.39]	+
	Total (95% CI) Heterogeneity: Chi ² = Test for overall effect:				; l² = 29	6	108	100.0%	0.15 [-0.12, 0.41] –	-1 -0.5 0 0.5 1 Favours [pioglitazonel] Favours [control]
Е		Pio	glitazo	one	Р	laceb	D		Std. Mean Difference	Std. Mean Difference
Е	Study or Subgroup		glitazo 1 SD					Weigh		Std. Mean Difference IV, Fixed, 95% Cl
E	<u>_Study or Subgroup</u> Belfort 2006		SD	Tota	I Mea				t IV, Fixed, 95% Cl	
E		Mean	SD 16	Tota	Mean 6 11	n SD 6 31	Total	21.0%	t IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11]	
E	Belfort 2006	<u>Mean</u> 99 128	SD 16	<u>Tota</u> 21 31	1 Mean 6 11 7 15	n SD 6 31	Total 21	21.0% 32.5%	IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11] 6 -0.78 [-1.26, -0.31]	
E	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI)	<u>Mean</u> 99 128 109	SD 16 31 12.5	Tota 20 31 50 113	<u>I Mear</u> 6 11 7 15 0 12 3	n <u>SD</u> 6 31 5 37 1 25	Total 21 36 51	21.0% 32.5%	IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11] 6 -0.78 [-1.26, -0.31] 6 -0.60 [-1.00, -0.20]	
E	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ²	<u>Mean</u> 99 128 109 *= 0.34, d	SD 16 3 31 12.5	<u>Tota</u> 20 33 5 50 113 P = 0.8	<u>I Mear</u> 6 110 7 159 0 12° 3 4); I ² = (n <u>SD</u> 6 31 5 37 1 25	Total 21 36 51	21.0% 32.5% 46.5%	IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11] 6 -0.78 [-1.26, -0.31] 6 -0.60 [-1.00, -0.20]	IV, Fixed, 95% Cl
Е	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI)	<u>Mean</u> 99 128 109 *= 0.34, d	SD 16 3 31 12.5	<u>Tota</u> 20 33 5 50 113 P = 0.8	<u>I Mear</u> 6 110 7 159 0 12° 3 4); I ² = (n <u>SD</u> 6 31 5 37 1 25	Total 21 36 51	21.0% 32.5% 46.5%	IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11] 6 -0.78 [-1.26, -0.31] 6 -0.60 [-1.00, -0.20]	
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ²	<u>99</u> 128 109 128 109 ₹= 0.34, d ct: Z = 4.9	SD 16 3 31 12.5	<u>Tota</u> 20 33 5 50 113 P = 0.8 0.0000	<u>I Mean</u> 6 11/ 7 15: 0 12: 3 4); I ² = (01)	n <u>SD</u> 6 31 5 37 1 25	Total 21 36 51 108	21.0% 32.5% 46.5%	IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11] 6 -0.78 [-1.26, -0.31] 6 -0.60 [-1.00, -0.20]	V, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ²	<u>Mean</u> 99 128 109 ² = 0.34, d ct: Z = 4.9 Pio	SD 16 318 12.5 If = 2 (F 1 (P <	Tota 20 31 5 5 113 P = 0.8 0.0000 one Tota	<u>I Mean</u> 6 111 7 15: 0 12 [:] 3 4); I ² = (01) F <u>I Mean</u>	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SE</u>	Total 21 36 51 108 0) Tota	21.0% 32.5% 46.5% 100.0%	t IV, Fixed, 95% Cl 6 -0.70 [-1.29, -0.11] 6 -0.78 [-1.26, -0.31] 6 -0.60 [-1.00, -0.20] 6 -0.68 [-0.95, -0.41] Std. Mean Difference	TV, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ^a Test for overall effer	<u>Mean</u> 99 128 109 ² = 0.34, d ct: Z = 4.9 Pio	SD 16 318 12.5 If = 2 (F 1 (P <	Tota 20 31 5 5 113 P = 0.8 0.0000 one Tota	<u>I Mean</u> 6 111 7 15: 0 12 [:] 3 4); I ² = (01) F <u>I Mean</u>	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SE</u>	Total 21 36 51 108 0) Tota	21.0% 32.5% 46.5% 100.0%	t IV, Fixed, 95% Cl -0.70 [-1.29, -0.11] -0.78 [-1.26, -0.31] -0.60 [-1.00, -0.20] -0.68 [-0.95, -0.41] Std. Mean Difference ht IV, Fixed, 95% Cl	V, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019	 Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 Maan 10 	SD 16 3 3 12.5 11 (P <	Tota 3 3 5 113 P = 0.8 0.0000 0.0000 Tota 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000	I Mean 6 110 7 159 0 120 3 4); I² = (01) F I Mean 6 18 7 19	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SE</u> 8 14 9 17	Total 21 36 51 108 0 <u>Tota</u> 4 2 7 3	21.0% 32.5% 46.5% 100.0% <u>1 Weiq</u> 1 20.5 6 33.7'	Image: two states	V, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect <u>Study or Subgroup</u> Belfort 2006 Bril 2019 Cusi 2016	 Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 Maan 10 	SD 16 3 3 12.5 11 (P <	$\begin{array}{c c} & Tota \\ & & 2i \\ & & 3i \\ & & 3i \\ & & 11i \\ P = 0.8 \\ 0.0000 \\ \hline & Tota \\ 0 \\ \hline & Tota \\ & & 3i \\ & & 3i \\ & & 50 \end{array}$	I Mean 3 110 7 155 0 12 3 4); I ² = (01) F I Mean 6 18 7 19 0 18	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SE</u> 8 14	Total 21 36 51 108 0 Tota 4 2 7 3 7 5	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8	Image: Note of the system New System State <	V, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI)	Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9	SD 16 312.5 12.5 11 (P <	Tota 5 20 33 35 5 50 113 20 2 0.0000 0 Tota 0 Tota 33 35 5 50 0 Tota 33 50 33 50 113 50	I <u>Mear</u> 5 111 7 153 0 12 3 4); I ² = (01) F I <u>Mear</u> 6 18 7 19 0 18 3	n SD 6 31 5 37 1 25 0% Placeb n SE 8 14 9 17 8 18.7	Total 21 36 51 108 0 Tota 4 2 7 3 7 5	21.0% 32.5% 46.5% 100.0% <u>1 Weiq</u> 1 20.5 6 33.7'	Image: Note of the system New System State <	V, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ²	Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 *= 0.70, d	SD 16 316 312.5 12.5 11 (P <	Tota 5 20 3: 5 5 50 11: 5 5 50 0.0000 0 0 Tota 0 Tota 0 Tota 0 Tota 3: 50 11: 50 0: Tota 0: Tota 0: Tota 0: 50 11: 50 0: 50	I <u>Mear</u> 5 111 7 153 0 12 3 4); I ² = (01) F I <u>Mear</u> 5 18 6 18 7 19 0 18 3 1); I ² = (n SD 6 31 5 37 1 25 0% Placeb n SE 8 14 9 17 8 18.7	Total 21 36 51 108 0 Tota 4 2 7 3 7 5	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8	Image: Note of the system New System State <	V, Fixed, 95% Cl -1 -0.5 0 0.5 1 Favours [pioglitazonel] Favours [control] Std. Mean Difference N, Fixed, 95% Cl -1 -0.5 0 0.5 1
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI)	Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 *= 0.70, d	SD 16 316 312.5 12.5 11 (P <	Tota 5 20 3: 5 5 50 11: 5 5 50 0.0000 0 0 Tota 0 Tota 0 Tota 0 Tota 3: 50 11: 50 0: Tota 0: Tota 0: Tota 0: 50 11: 50 0: 50	I <u>Mear</u> 5 111 7 153 0 12 3 4); I ² = (01) F I <u>Mear</u> 5 18 6 18 7 19 0 18 3 1); I ² = (n SD 6 31 5 37 1 25 0% Placeb n SE 8 14 9 17 8 18.7	Total 21 36 51 108 0 Tota 4 2 7 3 7 5	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8	Image: Note of the system New System State <	V, Fixed, 95% Cl
	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ²⁷ Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ²⁷ Test for overall effect	Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 *= 0.70, d ct: Z = 3.9	SD 3 16 3 31 3 12.5 if = 2 (if 2 (if = 2 (i	i Tota i 2i i 2i i 5i i 5i i 5i i 2i i 2i i 7 i 7 i 5i	I Mean 6 111 7 150 12 3 4); I ² = (0 3 12 3 12 3 12 3 12 3 15 1 Mean 5 18 3) 18 3) 19 1); I ² = 0 19	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SE</u> 8 14 9 17 3 18.7 9%	<u>Total</u> 21 36 51 108 0 <u>Tota</u> 4 2 7 3 7 5 10 10	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7' 1 45.8 8 100.0	Image: two states in the state state state state state	W, Fixed, 95% Cl Image: Cl
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect	Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 *= 0.70, d ct: Z = 3.9 Pic p Mean	SD 3 16 3 31 3 12.5 11 (P <	i Tota i 2i i 2i i 5i i 5i i 5i i 5i i 111: i 20.0000 i Tota i 700000 i 700000 i 500000 i 500000 i 500000 one 0.00000 one 0.00000	I Mean 6 111 7 15:0 10 12 3 12 4); I*= (0 101) I* I Mean 6 10 7 19 0 14 3 1); I*= 0 1) I* I* I* 10 14 3 1); I*= 0	n <u>SD</u> 6 31 5 37 1 25 0% <u>n SE</u> 8 14 9 17 8 18.7 9 17 8 18.7 9 9 17 8 18.7 9 9 17 8 18.7 9 9 17 9 17 9 17 9 18 9 9 17 9 18 9 9 17 9 9 17 9 9 9 17 9 9 17 9 9 17 9 17	<u>Total</u> 21 36 51 108 0 <u>Tota</u> 4 2 7 3 7 5 10 10 0 <u>Tota</u>	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7' 1 45.8 8 100.0 1 Weigt	Image: total system Image: total system <thimage: system<="" th="" total=""> Image: total system</thimage:>	V, Fixed, 95% Cl -1 -0.5 0 0.5 1 Favours [pioglitazonel] Favours [control] Std. Mean Difference IV, Fixed, 95% Cl -1 -0.5 0 0.5 1 Favours [pioglitazonel] Favours [control]
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006	 Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 *= 0.70, d ct: Z = 3.9 *= 0.70, d ct: Z = 3.9 Pico Mean 5.5 	SD 1 SD 3 16 3 31 3 12.5 if = 2 (if (P <	i Tota i 2i 3: 2i 3: 5 11: 5 5 51 5 50 0.0000 0 0.0000 0 0.0000 11:3 5 50 11:3 50 0.0000 11:3 5 50 0.0000 10:3 0.0000 10:3 0.0000 10:3 0.0000 10:3	I Mean 6 111 7 15:5 0 12:3 3 3 4); F= (1) 12 1 Mean 6 11; 1); F= (1) 14 3) 11; F= (2) 1); F= (2) 14 6 6	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SD</u> 8 14 9 17 8 18.7 9% Placeb n <u>SD</u> 1 0.9	Total 21 36 51 108 0	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8 8 100.0 1 45.8 8 100.0	Image: two stars Image: two stars total -0.70 [-1.29, -0.11] total -0.78 [-1.26, -0.31] total -0.60 [-1.00, -0.20] total -0.68 [-0.95, -0.41] total -0.68 [-0.95, -0.41] total -0.74 [-1.33, -0.14] total -0.74 [-1.33, -0.14] total -0.56 [-0.96, -0.16] total -0.55 [-0.82, -0.28] total -0.55 [-0.82, -0.28] total -0.70 [-1.29, -0.10]	W, Fixed, 95% Cl Image: Cl
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019	Mean 99 128 109 ct: Z = 4.9 Pio Mean 13 9 ct: Z = 3.9 ct: Z = 3.9 Pio Mean 13 9 4 0.70, d ct: Z = 3.9 Pio Mean 5.5.5 6.4	SD 1 SD 3 16 3 31 3 12.5 if = 2 (if	i Tota i 2i 3: 2i 3: 5 11: 5 5 51 11: 5 5 51 5 51 5 50 5 50 5 50 5 50 5 50 5 50 5 50 113: 50 5 50 6 10: 5 50 6 10: 7 20: 7 20: 6 50: 6 10: 7 20: 7 20: 6 10: 7 20: 7 20: 7 20: 7 20: 7 20: 7 20: 7 20:	I Mear 3 11:1 7 15:5 3 12: 3 14); I ^a = (01) I ^a Fear 3 11; I ^a = 0 1); I ^a = 0 1); I ^a = 0 1 1 1 1 1 1 1 1 1 1 1 1 1	n <u>SD</u> 6 31 5 37 1 25 9% Placeb n <u>SD</u> 1 8 18.7 9% Placeb n <u>SD</u> 1 0.9 2 1	Total 21 36 51 108 0	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8 8 100.0 1 Weigh 1 13.7 5 20.95	Image: Non-State State Number State Num	W, Fixed, 95% Cl Image: Cl
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006	 Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 *= 0.70, d ct: Z = 3.9 *= 0.70, d ct: Z = 3.9 Pico Mean 5.5 	SD 1 SD 1 16 3 31 3 31 3 31 3 31 1 12.5 1 1 1 7 3 11 1 12.5 If = 2 (F 0 7 3 11 1 12.5 If = 2 (F 0 0 1 12.5 1 5 0 0 1 12.5 0 5 1 5 0 0 1 0 0 0 0 0	<u> 1 Tota</u> 2(3) 3) 3) (13) (11) - - 0.0000 0000 0000 1 10 1 2(3) 1 1 2 3) 1 1 1 1 1 0 1 0 1 0 1	I Mean 6 11:1 7 15:5 0 12:2 3 3 4); F = (0 1 Mean 6 6. 6 6. 6 7. 7 7. 0 6.	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SD</u> 8 14 9 17 8 18.7 9% Placeb n <u>SD</u> 1 0.9	<u>Total</u> 21 36 51 108 0 <u>0</u> Tota 4 2 2 7 3 7 5 10 10 0 <u>Tota</u> 2 7 33 5 10 10	21.0% 32.5% 46.5% 100.0% 1 Veigl 1 20.5 6 33.7 1 45.8 8 100.0 1 Weigl 1 3.7% 5 20.9% 5 20.9% 1 30.1%	Image: two states in the state in the state in the states in th	W, Fixed, 95% Cl Image: Cl
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Yan 2015	Mean 99 128 109 *= 0.34, d ct: Z = 4.9 Pio Mean 10 *= 0.70, d ct: Z = 3.9 Pio Mean 10 *= 0.70, d ct: Z = 3.9 pio 0 Mean 5.5 6. 5.5	SD 1 SD 1 16 3 31 3 31 3 31 3 31 1 12.5 1 1 1 7 3 11 1 12.5 If = 2 (F 0 7 3 11 1 12.5 If = 2 (F 0 0 1 12.5 1 5 0 0 1 12.5 0 5 1 5 0 0 1 0 0 0 0 0	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\frac{I}{I} = \frac{Mean}{I}$ $\frac{I}{I} = \frac{I}{I}$ \frac	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SD</u> 1 3 0.6	Total 21 36 51 108 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8 8 100.0 1 30.1 6 20.9 6 20.9 1 30.1 2 35.3 9	Image: two stars Image: two stars total -0.70 [-1.29, -0.11] total -0.78 [-1.26, -0.31] total -0.78 [-1.26, -0.31] total -0.60 [-1.00, -0.20] total -0.68 [-0.95, -0.41] total -0.68 [-0.95, -0.41] total -0.74 [-1.33, -0.14] total -0.74 [-1.33, -0.14] total -0.42 [-0.88, 0.05] total -0.56 [-0.96, -0.16] total -0.55 [-0.82, -0.28] Std. Mean Difference IV, Fixed, 95% CI total -0.55 [-0.82, -0.28] Std. Mean Difference IV, Fixed, 95% CI total -0.70 [-1.29, -0.10] total -0.88 [-1.36, -0.39] total -0.83 [-1.20, -0.46]	W, Fixed, 95% Cl Image: Cl
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Yan 2015 Total (95% CI)	Mean 99 128 109 * = 0.34, d ct: Z = 4.9 Pio Mean 13 9 * = 0.70, d ct: Z = 3.9 Pio Mean 13 9 * = 0.70, d ct: Z = 3.9 Pio Mean 5.5 6. 5.4 5.5	$\begin{array}{c c} & SD \\ \hline & SD \\ \hline & SD \\ \hline & 16 \\ \hline & 3 \\ \hline & 16 \\ \hline & 3 \\ \hline & 16 \\ \hline & 16 \\ \hline & 12.5 \\ \hline \\ & glitazcc \\ \hline & glitazcc \\ \hline & 11 \\ \hline & SD \\ \hline & 11 \\ \hline & 12.5 \\ \hline \\ & 11 \\ \hline & SD \\ \hline & 11 \\ \hline \\ & 10 \\ \hline \\ & 12.5 \\ \hline \\ & 11 \\ \hline \\ & 10 \\ \hline \\ \\ \\ \\ & 10 \\ \hline \\ \\ \\ \\ \\ \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ $	i Tota i Tota i 22 3: 5 i 5 11: 5 P = 0.8 0.0000 one 1 i 10000 one 22 3: 3 i 50000 one 1113 one 0.0000 one 0.0000 one 3 3 2 3 3 3 2 3 3 5 6 5 6 17	I Mear 3 11: 7 15: 0 12: 3 4); I [≠] = (01) I [≠] = (1 Mear 5 11: 1 Mear 6 16 6. 7 7. 0 6. 0 6. 3	n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SD</u> 3 14 3 14 3 14 3 14 3 14 3 14 3 14 3 14	Total 21 36 51 108 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	21.0% 32.5% 46.5% 100.0% 1 Veigl 1 20.5 6 33.7 1 45.8 8 100.0 1 Weigl 1 3.7% 5 20.9% 5 20.9% 1 30.1%	Image: two stars Image: two stars total -0.70 [-1.29, -0.11] total -0.78 [-1.26, -0.31] total -0.60 [-1.00, -0.20] total -0.68 [-0.95, -0.41] total -0.68 [-0.95, -0.41] total -0.74 [-1.33, -0.14] total -0.74 [-1.33, -0.14] total -0.42 [-0.88, 0.05] total -0.55 [-0.82, -0.28] total -0.55 [-0.82, -0.28] total -0.70 [-1.29, -0.10] total -0.88 [-1.36, -0.39] total -0.83 [-1.20, -0.46]	V, Fixed, 95% Cl
F	Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Total (95% CI) Heterogeneity: Chi ² Test for overall effect Study or Subgroup Belfort 2006 Bril 2019 Cusi 2016 Yan 2015	 Mean 99 128 109 e 0.34, d ct: Z = 4.9 Pio Mean 10 13 9 e 0.70, d ct: Z = 3.9 Pio Mean 5.5 5.5 5.5 	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	I Mean 3 11: 7 15: 3 4); F = (4); F = (12: 3 1; F = (11) F 1 Mean 3 11; F = (1); F = (14: 3 11; F = (11); F = (0 10 17: 3 10: 10: F 11: Mean 6 6. 10: F 11: F 11: F = (3: F = (3: S = (3: S = (3: S = (n <u>SD</u> 6 31 5 37 1 25 0% Placeb n <u>SD</u> 3 14 3 14 3 14 3 14 3 14 3 14 3 14 3 14	Total 21 36 51 108 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	21.0% 32.5% 46.5% 100.0% 1 20.5 6 33.7 1 45.8 8 100.0 1 30.1 6 20.9 6 20.9 1 30.1 2 35.3 9	Image: two stars Image: two stars total -0.70 [-1.29, -0.11] total -0.78 [-1.26, -0.31] total -0.78 [-1.26, -0.31] total -0.60 [-1.00, -0.20] total -0.68 [-0.95, -0.41] total -0.68 [-0.95, -0.41] total -0.74 [-1.33, -0.14] total -0.74 [-1.33, -0.14] total -0.42 [-0.88, 0.05] total -0.56 [-0.96, -0.16] total -0.55 [-0.82, -0.28] Std. Mean Difference IV, Fixed, 95% CI total -0.55 [-0.82, -0.28] Std. Mean Difference IV, Fixed, 95% CI total -0.70 [-1.29, -0.10] total -0.88 [-1.36, -0.39] total -0.83 [-1.20, -0.46]	W, Fixed, 95% Cl Image: Cl

FIGURE 4 | The effect of pioglitazone on weight (A); the effect of pioglitazone on BMI (B); the effect of pioglitazone on total body fat (C); the effect of pioglitazone on HOMA-IR (D); the effect of pioglitazone on fasting plasma glucose (E); the effect of pioglitazone on fasting plasma insulin (F); and the effect of pioglitazone on HbA1c (G).



NAFLD on imaging (13–15). T2DM patients with NAFLD have higher all-cause, cardiovascular (CV), and liver-related mortality (3, 16). A 150-month follow-up study showed that T2DM doubled the risk of all-cause, liver-related death in NAFLD patients (17). Therefore, it is necessary to actively explore the treatment plan for T2DM patients with NAFLD.

The results of our meta-analysis show that the evidence from published RCTs suggests that pioglitazone could significantly improve glucose metabolism, liver function and liver histology, such as steatosis grade, inflammation grade and ballooning grade, although there was no significant difference in fibrosis between pioglitazone and placebo. However, our results show



FIGURE 6 | Effects of pioglitazone on the risk of adverse events in patients with pre-diabetes or T2DM combined with NAFLD (A); Effects of pioglitazone on the risk of discontinuations in patients with pre-diabetes or T2DM combined with NAFLD (B); Effects of pioglitazone on the risk of Serious Adverse Events in patients with pre-diabetes or T2DM combined with NAFLD (C).



that pioglitazone has efficacy in patients with T2DM combined with NFALD.

NASH is a more serious and progressive form of NAFLD and is characterized by inflammation and hepatocyte ballooning that set off fibrosis and pose a risk of developing cirrhosis and hepatocellular carcinoma (18, 19). In addition, studies through liver biopsy have found that approximately 30% to 50% of patients have steatohepatitis even in the presence of normal plasma aminotransferase levels (20–22). Our results show that pioglitazone can also significantly alleviate NASH in patients with prediabetes or T2DM combined with NAFLD.

In addition, pioglitazone significantly reduced plasma AST and ALT levels. Pioglitazone also significantly improved fasting glucose, HbA1c and plasma insulin levels. However, there were no significant effects on weight, BMI, total body fat, HDL or LDL compared with placebo.

Pioglitazone significantly increases the risk of adverse events, including hypoglycemia, chronic lower limb edema, atypical chest pain or epigastralgia and back or joint pain. There were two deaths in the pioglitazone arms and two in the placebo arms but insufficient power to detect an overall effect. However, because all of the studies we included were under 18 months, there is no proof so far that therapy with pioglitazone beyond 18 months brings additional histological benefits, and research in the future needs to clarify the optimal therapy duration and whether lower doses are beneficial. In addition, pioglitazone should be used with caution in T2DM patients due to the higher risk of heart failure (HF). Although a meta-analysis of 19 randomized controlled trials showed that pioglitazone treatment was associated with a reduced risk of major cardiovascular events, it was also associated with an increased risk of severe heart failure events (23).

At present, no meta-analysis has been conducted on pioglitazone in the treatment of prediabetes or T2DM patients with NAFLD. The results of a meta-analysis on NAFLD patients without T2DM showed that pioglitazone can significantly improve steatosis and inflammation but yielded significant weight gain. In addition, pioglitazone also reduced blood sugar, hemoglobin A1c, and other liver indicators, such as plasma triglycerides. This was broadly consistent with our results, except that our analysis showed no risk of weight gain, possibly due to inconsistencies in the inclusion of patients (24). Other meta-analyses also agreed on the beneficial effects of pioglitazone on lobular inflammation; however, there were still conflicting results for hepatic fibrosis (25, 26). The metaanalysis of Musso et al. showed that treatment with the antidiabetic drug pioglitazone reverses the more advanced stages of liver disease in NASH regardless of the presence of diabetes, but he combined T2DM with NAFLD and T2DM without NAFLD in a comprehensive analysis, which is still different from the study we included (27).

Recent guidelines recommend the identification of patients with advanced NAFLD with liver fibrosis and more intensive monitoring of the occurrence of complications but also acknowledge the lack of effective treatment options to reverse advanced liver disease. Our results also showed that pioglitazone was not effective in the treatment of liver fibrosis (28, 29).

Strengths and Limitations of This Study

NAFLD is a hot spot of recent research, and there are no specific guidelines for treatment plans for NAFLD patients. Currently, there are no drugs available for the treatment of NAFLD. Although the studies we included are limited, it is the first time that we have used the gold standard of liver biopsy as the main result and used a meta-analysis to comprehensively analyze the therapeutic effects of pioglitazone on glucose metabolism and liver biological indicators in patients with NAFLD. It should be mentioned that the limitations of our meta-analysis are related to the nature of the studies included. Currently, there are few randomized controlled trials involving pioglitazone in the treatment of NAFLD and T2DM, so we conducted a comprehensive analysis of NAFLD with IGT and NAFLD with T2DM. Second, we did not conduct a separate analysis of NASH and only analyzed it as an advanced NAFLD state. Finally, the sample size of the studies we included was also small, and the duration was less than 18 months, which also affected our analysis results to some extent. However, it should be noted that the American Association for the Study of Liver Diseases and the US Food and Drug Administration have the consensus that because of the progressive characteristics of nonalcoholic fatty liver disease, it is impractical and Infeasible to conduct large-scale, long-term studies to confirm treatment-related clinical benefits (30).

CONCLUSIONS

In conclusion, our results suggest that although pioglitazone has no significant effect on liver fibrosis, it can significantly improve liver histology, such as steatosis, inflammation and ballooning. Furthermore, pioglitazone can also improve insulin sensitivity and significantly reduce fasting blood glucose, glycosylated hemoglobin, plasma AST, ALT and other liver biological indicators. We suggest that pioglitazone can be used as a first-line therapy for NAFLD in the absence of FDA-approved pharmacological drugs for the treatment of T2DM patients with NAFLD, especially NASH.

It is also important to note that hypoglycemia, chronic lower limb edema, atypical chest pain or epigastralgia and back or joint pain are common side effects of pioglitazone treatment. In this regard, the risks and benefits should be considered before starting therapy.

In summary, due to the limitations of pioglitazone in the treatment of T2DM patients with NAFLD, such as fewer randomized controlled trials and shorter follow-up times, it is still necessary to design strict randomized controlled trials with large samples and long-term follow-up to prove the efficacy of pioglitazone to better guide clinical decision-making, patient selection and clinical practice guidelines.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

JL was mainly involved in electronic retrieval, abstract screening, data extraction, data analysis and manuscript review, while JF

REFERENCES

- Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. *Clin Gastroenterol Hepatol* (2019) 17(4):748–55. doi: 10.1016/j.cgh.2018.05.057
- 2. Byrne CD, Targher G. NAFLD: A Multisystem Disease. *J Hepatol* (2015) 62(1 Suppl):S47–64. doi: 10.1016/j.jhep.2014.12.012
- Younossi ZM, Golabi P, De Avila L, Paik JM, Srishord M, Fukui N, et al. The Global Epidemiology of NAFLD and NASH in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Hepatol (2019) 71 (4):793–801. doi: 10.1016/j.jhep.2019.06.021
- 4. Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, et al. European Association for the Study of the Liver (Easl), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) Clinical Practice Recommendations for the Management of non-Alcoholic Fatty Liver Disease: Evaluation of Their Application in People With Type 2 Diabetes. *Diabetes Med* (2018) 35(3):368–75. doi: 10.1111/ dme.13565
- Jang JE, Cho Y, Lee BW, Shin ES, Lee SH. Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis. *Diabetes Metab J* (2019) 43(3):302–18. doi: 10.4093/dmj.2018.0062
- Kim KS, Lee BW. Beneficial Effect of Anti-Diabetic Drugs for Nonalcoholic Fatty Liver Disease. *Clin Mol Hepatol* (2020) 26(4):430–43. doi: 10.3350/ cmh.2020.0137
- Shah PK, Mudaliar S, Chang AR, Aroda V, Andre M, Burke P, et al. Effects of Intensive Insulin Therapy Alone and in Combination With Pioglitazone on Body Weight, Composition, Distribution and Liver Fat Content in Patients With Type 2 Diabetes. *Diabetes Obes Metab* (2011) 13(6):505–10. doi: 10.1111/j.1463-1326.2011.01370.x
- Le P, Chaitoff A, Rothberg MB, McCullough A, Alkhouri N. Trends in Pioglitazone Use Among U.S. Adults With Type 2 Diabetes and Suspected Nonalcoholic Fatty Liver Disease. *Expert Opin Investig Drugs* (2020) 29 (2):205–8. doi: 10.1080/13543784.2020.1704731
- Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, et al. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. *Diabetes Care* (2019) 42(8):1481– 8. doi: 10.2337/dc19-0167
- Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med (2016) 165(5):305–15. doi: 10.7326/M15-1774
- Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A Placebo-Controlled Trial of Pioglitazone in Subjects With Nonalcoholic Steatohepatitis. N Engl J Med (2006) 355(22):2297–307. doi: 10.1056/NEJMoa060326
- Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, et al. Efficacy of Berberine in Patients With Non-Alcoholic Fatty Liver Disease. *PloS One* (2015) 10(8):e0134172. doi: 10.1371/journal.pone.0134172
- Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty

was mainly involved in method design, electronic retrieval, abstract screening, data extraction, data analysis and interpretation and manuscript review. All authors contributed to the article and approved the submitted version.

FUNDING

This research was funded by the National Natural Science Foundation of China (81670736).

Liver Disease in People With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study. *Diabetes Care* (2011) 34(5):1139–44. doi: 10.2337/dc10-2229

- Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and Associated Factors of non-Alcoholic Fatty Liver Disease in Patients With Type-2 Diabetes Mellitus. *Liver Int* (2009) 29(1):113–9. doi: 10.1111/j.1478-3231.2008.01718.x
- Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, et al. Liver Fat is Increased in Type 2 Diabetic Patients and Underestimated by Serum Alanine Aminotransferase Compared With Equally Obese Nondiabetic Subjects. *Diabetes Care* (2008) 31(1):165–9. doi: 10.2337/dc07-1463
- Wild SH, Walker JJ, Morling JR, Westerbacka J, Cornér A, Bergholm R, et al. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. *Diabetes Care* (2018) 41(2):341–7. doi: 10.2337/dc17-1590
- Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients With non-Alcoholic Fatty Liver Disease (NAFLD). *Dig Dis Sci* (2013) 58 (10):3017–23. doi: 10.1007/s10620-013-2743-5
- Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. *Front Pharmacol* (2019) 10:877. doi: 10.3389/fphar.2019.00877
- Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, et al. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. *Diabetes Metab* J (2019) 43(1):31–45. doi: 10.4093/dmj.2019.0011
- Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab (2015) 100(6):2231–8. doi: 10.1210/jc.2015-1966
- Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The Role of Liver Fat and Insulin Resistance as Determinants of Plasma Aminotransferase Elevation in Nonalcoholic Fatty Liver Disease. *Hepatology* (2015) 61(1):153–60. doi: 10.1002/hep.27395
- 22. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological Stages of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes: Prevalences and Correlated Factors. *Liver Int* (2011) 31(5):700–6. doi: 10.1111/j.1478-3231.2011.02482.x
- Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Trials. *JAMA* (2007) 298(10):1180–8. doi: 10.1001/ jama.298.10.1180
- Musso G, Gambino R, Cassader M, Pagano G. A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease. *Hepatology* (2010) 52(1):79–104. doi: 10.1002/hep.23623
- Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative Effectiveness of Pharmacological Interventions for Nonalcoholic Steatohepatitis: A Systematic Review and Network Meta-Analysis. *Hepatology* (2015) 62(5):1417-32. doi: 10.1002/hep.27999
- He L, Liu X, Wang L, Yang Z. Thiazolidinediones for Nonalcoholic Steatohepatitis: A Meta-Analysis of Randomized Clinical Trials. *Med* (*Baltimore*) (2016) 95(42):e4947. doi: 10.1097/MD.000000000004947
- 27. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-Analysis.

JAMA Intern Med (2017) 177(5):633–40. doi: 10.1001/jamainternmed. 2016.9607

- 28. European Association for the Study of The L, European Association for the Study Of D and European Association for the Study Of O. Easl-Easd-Easo Clinical Practice Guidelines for the Management of non-Alcoholic Fatty Liver Disease. *Diabetologia* (2016) 59(6):1121–40. doi: 10.1007/s00125-016-3902-y
- Glen J, Floros L, Day C, Pryke R. Non-Alcoholic Fatty Liver Disease (NAFLD): Summary of NICE Guidance. BMJ (2016) 354:i4428. doi: 10.1136/bmj.i4428
- 30. Sanyal AJ, Friedman SL, Mccullough AJ, Dimick-Santos L. Challenges and Opportunities in Drug and Biomarker Development for Nonalcoholic Steatohepatitis: Findings and Recommendations From an American Association for the Study of Liver Diseases-U.s. Food and Drug

Administration Joint Workshop. *Hepatology* (2015) 61(4):1392-405. doi: 10.1002/hep.27678

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lian and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.